<DOC>
	<DOCNO>NCT02715401</DOCNO>
	<brief_summary>To investigate pharmacokinetic property safety administration HCP1303 co-administration HGP1201 , HIP1402 Fed Condition healthy male volunteer</brief_summary>
	<brief_title>PK Safety HCP1303 Co-administration HGP1201 , HIP1402 Under Fed Condition Healthy Male Volunteers</brief_title>
	<detailed_description>The purpose study investigate Pharmacokinetic Properties Safety administration HCP1303 capsule Co-administration HGP1201 tablet , HIP1402 capsule Fed Condition Healthy Male Volunteers</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<criteria>1 . Healthy male volunteer , age 19~55 year 2 . The result Body Mass Index ( BMI ) less 19 kg/m2 , 27 kg/m2 3 . Subject ability comprehend study objective , content property study drug participate trial 4 . Subject ability willingness participate whole period trial 1 . Presence medical history concurrent disease may interfere treatment safety assessment completion clinical study , include clinically significant disorder kidney , liver , cardiovascular system , respiratory system , endocrine system , neuropsychiatric system . 2 . History relevant drug allergy clinically significant hypersensitivity reaction . 3 . Glomerular filtration rate 60ml/min calculate serum creatinine value . 4 . Liver enzyme ( AST , ALT ) level exceeds maximum normal range one half time . 5 . SBP : low 90mmHg high 150mmHg , DBP : low 60mmHg high 100mmHg 6 . Subjects judge ineligible investigator .</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>